The Role of Surgery After Remission of Nonsystemic Extensive Periorbital Basal Cell Carcinoma Treated by Vismodegib: A Systematic Review
CONCLUSION
Vismodegib is a well-tolerated treatment for advanced periorbital BCC. The hedgehog signaling pathway inhibitor vismodegib is a potential treatment option in patients with these challenging tumors.
Source: Dermatologic Surgery - Category: Dermatology Tags: Review Article Source Type: research
More News: Basal Cell Carcinoma | Cancer & Oncology | Carcinoma | Databases & Libraries | Dermatology | Neoadjuvant Therapy | Skin | Skin Cancer | Study